Compare PUBM & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | CGEM |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 671.7M |
| IPO Year | 2020 | 2021 |
| Metric | PUBM | CGEM |
|---|---|---|
| Price | $9.21 | $10.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $18.45 | ★ $27.14 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $288,382,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.01 | $5.68 |
| 52 Week High | $17.32 | $13.60 |
| Indicator | PUBM | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 58.77 |
| Support Level | $8.91 | $10.01 |
| Resistance Level | $9.24 | $13.33 |
| Average True Range (ATR) | 0.35 | 1.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 61.62 | 47.06 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.